XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
shares in Millions
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
contract
position
shares
Sep. 30, 2024
USD ($)
shares
Jun. 30, 2025
USD ($)
Sep. 30, 2025
USD ($)
segment
contract
position
shares
Sep. 30, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
Jan. 31, 2010
cvr
Property, Plant and Equipment              
Number of operating segments | segment       1      
Number of reportable segments | segment       1      
Gain on sale of Pelthos business       $ 53,072,000 $ 0    
Revenue recognized that was previously deferred $ 0 $ 200,000   $ 600,000 $ 1,200,000    
Sale of viking common stock (in shares) | shares 0.0 0.0   0.0 0.7    
Gain on sale of viking common stock         $ 60,000,000    
Number of positions in an unrealized loss position | position 73     73      
Unrealized losses $ (170,000)     $ (170,000)      
Credit losses related to available-for-sale debt securities 0 $ 0   0 0    
Amortized cost         50,000.00    
Increase (decrease) in allowance for credit losses 300,000 (200,000)   400,000 (300,000)    
Inventory write-down 0 100,000   0 200,000    
Inventory 11,900,000     11,900,000   $ 14,114,000  
Fair value adjustments to partner program derivatives 833,000 (7,812,000)   0 (7,812,000)    
Loss from equity method investment in Primrose Bio       0 5,763,000    
Equity method investments 42,000,000     42,000,000   $ 0  
Observable price changes $ 0 (30,000.00)   $ 0 (25,790,000)    
Agenus Warrant              
Property, Plant and Equipment              
Fair value adjustments to partner program derivatives   (8,000,000)     (6,800,000)    
Primrose mRNA              
Property, Plant and Equipment              
Investment owned, net assets, percentage 31.50%     31.50%   31.40%  
Loss from equity method investment in Primrose Bio   1,200,000     5,800,000    
Equity method investments           $ 0  
Impairment of equity method investment $ 0     $ 0 (5,800,000)    
Vikings              
Property, Plant and Equipment              
Fair value adjustments to partner program derivatives   (7,900,000)     7,300,000    
Performance Shares              
Property, Plant and Equipment              
Performance period for awards (in years)       3 years      
Metabasis Therapeutics              
Property, Plant and Equipment              
Number of contingent value rights issued | cvr             4
Minimum | Performance Shares              
Property, Plant and Equipment              
Payout range (as a percent)       0.00%      
Maximum | Performance Shares              
Property, Plant and Equipment              
Payout range (as a percent)       200.00%      
Partner Programs              
Property, Plant and Equipment              
Fair value adjustments to partner program derivatives $ (700,000)     $ (100,000)      
Agenus Partnered Program | Primordial Genetics              
Property, Plant and Equipment              
Number of contracts | contract 2     2      
Agenus Bot/Bal              
Property, Plant and Equipment              
Fair value adjustments to partner program derivatives   $ (7,200,000) $ (500,000)        
Primrose mRNA              
Property, Plant and Equipment              
Fair value adjustments to partner program derivatives     (600,000)   $ (600,000)    
Castle Creek Investment              
Property, Plant and Equipment              
Fair value adjustments to partner program derivatives     $ 300,000        
Limbach Holdings, Inc              
Property, Plant and Equipment              
Gain on sale of Pelthos business $ 53,100,000     $ 53,100,000      
Captisol              
Property, Plant and Equipment              
Inventory $ 2,300,000     $ 2,300,000   $ 3,100,000  
Primrose mRNA              
Property, Plant and Equipment              
Percentage of milestones (as a percent) 50.00%     50.00%